Work

SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform

Year: 2018

Type: article

Source: Cell chemical biology

DOI: 10.1016/j.chembiol.2018.01.013

Authors: John M. Hatcher, Guowei Wu, Chuyue Zeng, Jie Zhu, Fan Meng, Sherrina Patel, Wenqiu Wang, Scott B. Ficarro, Alan L. Leggett, Chelsea E. Powell, Jarrod A. Marto, Kang Zhang, Jacky Chi Ki Ngo, Xiang-Dong Fu, Tinghu Zhang, Nathanael S. Gray

Institutions: Harvard University, Dana-Farber Cancer Institute, University of California San Diego, Chinese University of Hong Kong, Guangzhou Women and Children Medical Center, Guangzhou Medical University, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center, Dana-Farber/Harvard Cancer Center

Language: English

Topic: RNA Research and Splicing

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Cancer Institute, Cairo University, National Cancer Institute, National Institute of General Medical Sciences

Awards: Targeting ALK through Degradation and Allosteric Inhibitors, Phosphoproteomic signatures for early detection and stratification of AML, Regulation of RNA metabolism and cell growth control by SR protein kinases, G5494590982, Cancer Biology, Informatics & Omics (CBIO) Training Program

OpenAlex ID: W2789218745

FWCI: 5.514

Cites: 74

Cited by: 133

Related to: 10